Literature DB >> 26643784

Time for Glucagon like peptide-1 receptor agonists treatment for patients with NAFLD?

Amalia Gastaldelli1, Giulio Marchesini2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26643784     DOI： 10.1016/j.jhep.2015.11.031

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  11 in total

Review 1.  The role of the gut microbiota in NAFLD.

Authors:  Christopher Leung; Leni Rivera; John B Furness; Peter W Angus
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-06-08       Impact factor: 46.802

Review 2.  Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force.

Authors:  Sanjay Kalra; Ashok Kumar Das; Rakesh Kumar Sahay; Manash Pratim Baruah; Mangesh Tiwaskar; Sambit Das; Sudip Chatterjee; Banshi Saboo; Ganapathi Bantwal; Saptarshi Bhattacharya; Gagan Priya; Manoj Chawla; Kiraninder Brar; Syed Abbas Raza; Azizul Hasan Aamir; Dina Shrestha; Noel Somasundaram; Prasad Katulanda; Faria Afsana; Shahjada Selim; Mohammad Wali Naseri; Ali Latheef; Manilka Sumanatilleke
Journal:  Diabetes Ther       Date:  2019-07-29       Impact factor: 2.945

Review 3.  Pathophysiology of Non Alcoholic Fatty Liver Disease.

Authors:  Salvatore Petta; Amalia Gastaldelli; Eleni Rebelos; Elisabetta Bugianesi; Piergiorgio Messa; Luca Miele; Gianluca Svegliati-Baroni; Luca Valenti; Ferruccio Bonino
Journal:  Int J Mol Sci       Date:  2016-12-11       Impact factor: 5.923

Review 4.  Pharmacological Therapy of Non-Alcoholic Fatty Liver Disease: What Drugs Are Available Now and Future Perspectives.

Authors:  Grazia Pennisi; Ciro Celsa; Federica Spatola; Marcello Dallio; Alessandro Federico; Salvatore Petta
Journal:  Int J Environ Res Public Health       Date:  2019-11-07       Impact factor: 3.390

Review 5.  From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options.

Authors:  Amalia Gastaldelli; Kenneth Cusi
Journal:  JHEP Rep       Date:  2019-07-19

6.  Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis.

Authors:  Chloe Wong; Ming Hui Lee; Clyve Yu Leon Yaow; Yip Han Chin; Xin Lei Goh; Cheng Han Ng; Amanda Yuan Ling Lim; Mark Dhinesh Muthiah; Chin Meng Khoo
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-09       Impact factor: 5.555

7.  A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D).

Authors:  Samit Ghosal; Debasis Datta; Binayak Sinha
Journal:  Sci Rep       Date:  2021-11-11       Impact factor: 4.379

8.  Hepatoprotection of Probiotics Against Non-Alcoholic Fatty Liver Disease in vivo: A Systematic Review.

Authors:  Faezah Sabirin; Siong Meng Lim; Chin Fen Neoh; Kalavathy Ramasamy
Journal:  Front Nutr       Date:  2022-04-11

Review 9.  Personalizing Diabetes Management in Liver Transplant Recipients: The New Era for Optimizing Risk Management.

Authors:  Kymberly D Watt; Manhal Izzy; Brooks Richardson; Mohammad Qasim Khan; Sara A Brown
Journal:  Hepatol Commun       Date:  2021-12-17

Review 10.  Nonalcoholic Fatty Liver Disease.

Authors:  Lingling Ding; Yvonne Oligschlaeger; Ronit Shiri-Sverdlov; Tom Houben
Journal:  Handb Exp Pharmacol       Date:  2022
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.